VOR Stock Overview
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Vor Biopharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.88 |
| 52 Week High | US$5.70 |
| 52 Week Low | US$1.62 |
| Beta | -0.36 |
| 1 Month Change | -7.84% |
| 3 Month Change | -21.01% |
| 1 Year Change | -57.75% |
| 3 Year Change | -93.46% |
| 5 Year Change | n/a |
| Change since IPO | -94.99% |
Recent News & Updates
Recent updates
Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation
Dec 05
Will Vor Biopharma (NASDAQ:VOR) Spend Its Cash Wisely?
Aug 18Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans
May 05Is Vor Biopharma Inc. (NASDAQ:VOR) Trading At A 49% Discount?
Mar 13We Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth Carefully
Oct 19Vor Bio appoints Eyal C. Attar as chief medical officer
Oct 12Is Vor Biopharma (NASDAQ:VOR) In A Good Position To Invest In Growth?
Jun 18Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans
Mar 05Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans
Aug 30Vor Biopharma: Targeted Therapies For Transplants
Jun 30We're Not Very Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate
May 10Vor Biopharma EPS misses by $0.03
May 06Shareholder Returns
| VOR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 8.7% | 1.5% | 1.2% |
| 1Y | -57.8% | 1.1% | 24.7% |
Return vs Industry: VOR underperformed the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: VOR underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| VOR volatility | |
|---|---|
| VOR Average Weekly Movement | 9.8% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VOR's share price has been volatile over the past 3 months.
Volatility Over Time: VOR's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 168 | Robert Ang | www.vorbio.com |
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML.
Vor Biopharma Inc. Fundamentals Summary
| VOR fundamental statistics | |
|---|---|
| Market cap | US$128.25m |
| Earnings (TTM) | -US$117.86m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.1x
P/E RatioIs VOR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VOR income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$117.86m |
| Earnings | -US$117.86m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.73 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did VOR perform over the long term?
See historical performance and comparison